Cardiac side effects of anticancer treatments: New mechanistic insights

Current Heart Failure Reports

Volumn 9, Issue 3, 2012, Pages 211-218

  Geisberg, Carrie ^a   Pentassuglia, Laura ^b   Sawyer, Douglas B ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adriamycin; Anthracycline; Cardiac progenitor cell; Cardiac toxicity; Cardio oncology; Daunorubicin; Doxorubicin; Erbb2; Heart failure; Herceptin; Sorafenib; Sunitinib; Therapy; Trastuzumab; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANERTINIB; CETUXIMAB; DAUNORUBICIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE; DOXORUBICIN; ERLOTINIB; GEFITINIB; LAPATINIB; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAZOXANE; SORAFENIB; SUNITINIB; TRASTUZUMAB; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; HEART DISEASE; HEART FAILURE; HEART INJURY; HEART PROTECTION; HOMEOSTASIS; HUMAN; NEOPLASM; NONHUMAN; ONCOGENE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEART CONTRACTION; HEART MUSCLE CELL; REVIEW;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; DAUNORUBICIN; DOXORUBICIN; HEART FAILURE; HUMANS; INDOLES; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PYRIDINES; PYRROLES;

EID: 84871859703     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0098-4     Document Type: Article

References (93)

1. Arcamone F, Di Marco A, Gaetani M, et al. Isolation and antitumor activity of an antibiotic from Streptomycse. G Microbiology. 1961;9:83.
2. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1-10. This review was written by an interdisciplinary team of investigators who convened to discuss the known and unknown aspects of how cancer therapies affect the heart. The position statement provides a useful resource for investigators embarking on studying cardiac effects of cancer therapies.
3. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure 1979;91(5):710-7.
4. Sawyer DB, Zuppinger C, Miller TA, et al. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105 (13):1551-4. (Pubitemid 34297631)
5. Sawyer DB, Fukazawa R, Arstall MA, et al. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84(3):257-65. (Pubitemid 29095566)
6. Lambertenghi-Deliliers G, Zanon PL, Pozzoli EF, et al. Myocardial injury induced by a single dose of adriamycin: an electron microscopic study 1976;62(5):517-28.
7. Unverferth DV, Magorien RD, Unverferth BP, et al. Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration 1981;65(11-12):1093-7.
8. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96(8):2641-8. (Pubitemid 27451357)
9. Yoshida M, Shiojima I, Ikeda H, et al. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-Apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol. 2009;47(5):698-705.
10. Ward DC, Reich E, Goldberg IH. Base specificity in the interaction of polynucleotides with antibiotic drugs. Science. 1965;149 (3689):1259-63.
11. Di Marco A, Silvestrini R, Di Marco S, et al. Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells. J Cell Biol. 1965;27(3):545-50.
12. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226(4673):466-8. (Pubitemid 14012819)
13. Icli B, Bharti A, Pentassuglia L, et al. ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochem Biophys Res Commun. 2012;418(1):116-21.
14. Terrand J, Xu B, Morrissy S, et al. p21(WAF1/Cip1/Sdi1) knockout mice respond to doxorubicin with reduced cardiotoxicity. Toxicol Appl Pharmacol. 2011;257(1):102-10.
15. Velez JM, Miriyala S, Nithipongvanitch R, et al. p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One. 2011;6(3): e18005.
16. Shizukuda Y, Matoba S, Mian OY, et al. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol Cell Biochem. 2005;273(1-2):25-32. (Pubitemid 40774760)
17. Feridooni T, Hotchkiss A, Remley-Carr S, et al. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS One. 2011;6(7):e22801.
18. Ji LL, Mitchell EW. Effects of Adriamycin on heart mitochondrial function in rested and exercised rats. Biochem Pharmacol. 1994;47 (5):877-85. (Pubitemid 24087417)
19. Maslov MY, Chacko VP, Hirsch GA, et al. Reduced in vivo highenergy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2010;299(2):H332-7.
20. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279(9):8290-9. (Pubitemid 38294721)
21. Sterba M, Popelova O, Lenco J, et al. Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol. 2011;50 (5):849-62.
22. Jeyaseelan R, Poizat C, Baker RK, et al. A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes 1997;272 (36):22800-8.
23. Park AM, Nagase H, Liu L, et al. Mechanism of anthracyclinemediated down-regulation of GATA4 in the heart. Cardiovasc Res. 2011;90(1):97-104.
24. Liu J, Zheng H, Tang M, et al. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am J Physiol Heart Circ Physiol. 2008;295(6):H2541-50.
25. Aries A, Paradis P, Lefebvre C, et al. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci U S A. 2004;101(18):6975-80. (Pubitemid 38596428)
26. Chen B, Zhong L, Roush SF, et al. Disruption of a GATA4/Ankrd1 Signaling Axis in Cardiomyocytes Leads to Sarcomere Disarray: Implications for Anthracycline Cardiomyopathy. PLoS ONE. 2012;7(4):e35743. This basic investigation demonstrates GATA4 and Ankrd1 (aka CARP) co-regulate transcription of sarcomeric proteins in cardiac myocytes. Anthracycline disruption of both GATA4 and subsequent CARP expression ultimately contributes to the sarcomere disorganization in cardiac myocytes.
27. Scott JM, Khakoo A, Mackey JR, et al. Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124(5):642-50.
28. HelmesM, LimCC, Liao R, et al. Titin determines the Frank-Starling relation in early diastole. J Gen Physiol. 2003;121(2):97-110. (Pubitemid 36255340)
29. Granzier H, Kellermayer M, Helmes M, et al. Titin elasticity and mechanism of passive force development in rat cardiac myocytes probed by thin-filament extraction. Biophys J. 1997;73(4):2043-53. (Pubitemid 27425734)
30. Sag CM, Kohler AC, AndersonME, et al. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol. 2011;51(5):749-59.
31. Hanna AD, Janczura M, Cho E, et al. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol. 2011;80(3):538-49.
32. Cochet A, Quilichini G, Dygai-Cochet I, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011;130(3):845-54. This study demonstrates that baseline subtle abnormalities in cardiac function predict which patients undergoing treatment with trastuzumab may go on to develop further cardiac dysfunction. This will lead to further research examining whether such measures can be used to institute cardioprotective strategies that prevent these events.
33. Ho E, Brown A, Barrett P, et al. Subclinical anthracycline- And trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study. Heart. 2010;96(9):701-7.
34. Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol. 1996;14 (2):328-31. (Pubitemid 26050991)
35. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15(4):1318-32. (Pubitemid 27167363)
36. Menna P, Salvatorelli E, Minotti G. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival. Chem Res Toxicol. 2010;23(1):6-10.
37. Inaba M, Kobayashi H, Sakurai Y, et al. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res. 1979;39(6 Pt 1):2200-3. (Pubitemid 9177932)
38. Gottesman MM, Pastan I. The multidrug transporter, a doubleedged sword. J Biol Chem. 1988;263(25):12163-6.
39. Cordon-Cardo C, O'Brien JP, Boccia J, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38(9):1277-87. (Pubitemid 20266126)
40. Jungsuwadee P, Cole MP, Sultana R, et al. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol Cancer Ther. 2006;5 (11):2851-60. (Pubitemid 44849012)
41. van Asperen J, van Tellingen O, Tijssen F, et al. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer. 1999;79(1):108-13. (Pubitemid 28566934)
42. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112 (24):3754-62. (Pubitemid 43739516)
43. Deng S, Wojnowski L. Genotyping the risk of anthracyclineinduced cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):129-34.
44. Cardinale D, Colombo A, Lamantia G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213-20.
45. Beltrami AP, Barlucchi L, Torella D, et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell. 2003;114(6):763-76. (Pubitemid 37186770)
46. Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102.
47. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121(2):276-92.
48. Huang C, Zhang X, Ramil JM, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation. 2010;121(5):675-83. This investigation established that anthracyclines reduce the number of cardiac progenitor cells in young mice. They go on to demonstrate that the mice then have adverse response to exercise induced cardiac hypertrophy. This study opens up a novel mechanism for cardiotoxicity of anthracyclines, particularly in the heart. It further suggests that strategies that preserve or restore progenitor cell populations may have therapeutic potential for anthracycline-Associated cardiomyopathy.
49. Pfister O, Oikonomopoulos A, Sereti KI, et al. Role of the ATPbinding cassette transporter Abcg2 in the phenotype and function of cardiac side population cells. Circ Res. 2008;103(8):825-35.
50. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13(1):63-72. (Pubitemid 26248546)
51. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network 2001;2(2):127-37.
52. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344 (11):783-92. (Pubitemid 32222155)
53. Erickson SL, O'Shea KS, Ghaboosi N, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-And heregulin-deficient mice. Development. 1997;124 (24):4999-5011. (Pubitemid 28025125)
54. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor [see comments] 1995;378(6555):390-4.
55. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development [see comments] 1995;378(6555):394-8.
56. Meyer D, Birchmeier C.Multiple essential functions of neuregulin in development [see comments] [published erratum appears in Nature 1995 Dec 14;378(6558):753]. 1995 1995/11/23/;378(6555):386-90.
57. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273(17):10261-9. (Pubitemid 28227629)
58. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8(5):459-65. (Pubitemid 34546747)
59. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880-5. (Pubitemid 34693652)
60. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44(11):2231-8. (Pubitemid 39576044)
61. Fukazawa R, Miller TA, Kuramochi Y, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 2003;35(12):1473-9. (Pubitemid 37491190)
62. Gordon LI, Burke MA, Singh AT, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284(4):2080-7.
63. Singh KK, Shukla PC, Quan A, et al. Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death. Biochem Biophys Res Commun. 2011;411(2):421-6.
64. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23 (31):7820-6. (Pubitemid 46657379)
65. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2- dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41 (2):228-35. (Pubitemid 44080212)
66. Timolati F, Ott D, Pentassuglia L, et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol. 2006;41(5):845-54. (Pubitemid 44635571)
67. Russell KS, Stern DF, Polverini PJ, et al. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999;277(6 Pt 2):H2205-11. (Pubitemid 30048139)
68. Hedhli N, Russell KS. Cytostatic drugs, neuregulin activation of erbB receptors, and angiogenesis. Curr Hypertens Rep. 2010;12 (6):411-7.
69. Kupatt C, Hinkel R, Lamparter M, et al. Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase. Circulation. 2005;112(9 Suppl):I117-22. (Pubitemid 41266662)
70. Safa RN, Peng XY, Pentassuglia L, et al. Neuregulin-1beta regulation of embryonic endothelial progenitor cell survival. Am J Physiol Heart Circ Physiol. 2011;300(4):H1311-9.
71. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer. 2006;6(9):714-27. (Pubitemid 44286003)
72. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111- labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24(15):2276-82. (Pubitemid 46630657)
73. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indiumtrastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43 (14):2046-51.
74. Pentassuglia L, Graf M, Lane H, et al. Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res. 2009;315(7):1302-12.
75. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43. (Pubitemid 46021510)
76. Spector NL, Yarden Y, Smith B, et al. Activation of AMP-Activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci U S A. 2007;104(25):10607-12. (Pubitemid 47185712)
77. Allen LF, Eiseman IA, Fry DW, et al. CI-1033, an irreversible panerbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol. 2003;30(5 Suppl 16):65-78. (Pubitemid 37433398)
78. Rixe O, Franco SX, Yardley DA, et al. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. 2009;64(6):1139-48.
79. Sawyer DB, Caggiano A. Neuregulin-1beta for the treatment of systolic heart failure. J Mol Cell Cardiol. 2011;51(4):501-5.
80. Fernandez SV, Snider KE, Wu YZ, et al. DNA methylation changes in a human cell model of breast cancer progression. Mutat Res. 2010;688(1-2):28-35.
81. Nalwoga H, Arnes JB, Stefansson IM, et al. Vascular proliferation is increased in basal-like breast cancer. Breast Cancer Res Treat. 2011;130(3):1063-71.
82. Steingart RM, Bakris GL, Chen HX, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163(2):156-63.
83. Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011;80(12):1271-7.
84. Izumiya Y, Shiojima I, Sato K, et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension. 2006;47(5):887-93. (Pubitemid 44297560)
85. Khakoo AY, Kassiotis CM, Tannir N, et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer. 2008;112(11):2500-8.
86. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24. (Pubitemid 46089672)
87. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329- 38. (Pubitemid 44528723)
88. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011-9. (Pubitemid 350236338)
89. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204-12.
90. Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-Activated protein kinase. Clin Transl Sci. 2009;2(1):15-25.
91. Chintalgattu V, Ai D, Langley RR, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest. 2010;120 (2):472-84. This basic investigation was motivated by effects of multi-tyrosine kinase inhibitors such as sunitinib on cardiac function. Sunitinib inhibits the activity of the PDGF receptor. The investigators show that mice lacking the PDGFR have accelerated heart failure in response to pressure overload. In addition to providing a potential mechanism for the effect of sunitinib on the heart, the study may stimulate reverse translation to examine whether PDGFR signaling can be manipulated to improve outcome in heart failure.
92. Young LH, Li J, Baron SJ, et al. AMP-Activated protein kinase: a key stress signaling pathway in the heart. Trends Cardiovasc Med. 2005;15(3):110-8. (Pubitemid 41021735)
93. Peng X, Pentassuglia L, Sawyer DB. Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concerň Circ Res. 2010;106(6):1022-34.